Lifileucel Linked to Low Post-Discharge Severe TRAEs in Advanced Melanoma
OncLive reports low rates of post-discharge severe TRAEs and hospital readmissions after lifileucel in advanced melanoma. Cohort details and follow-up window remain undisclosed in the summary.